InvestorsHub Logo
Followers 971
Posts 382972
Boards Moderated 18
Alias Born 06/24/2011

Re: None

Wednesday, 07/01/2015 10:48:15 AM

Wednesday, July 01, 2015 10:48:15 AM

Post# of 10976
"Liliana and Frank and the Mel-Mont team bring a wealth of expertise; we are enormously appreciative to be commercialization partners with them," said Kevin Sorrels, CEO of GVDI.

Through its unique approach to product development, Mel-Mont Medical has developed a one-of-a-kind medical device kit that empowers women to test for cervical cancer. Unlike traditional screening using Pap smear, woman can now use XytoTest™ in a private setting to avoid the embarrassment, anxiety, or fear caused by the regular cytology. The key drivers of the Company's product development approach include: Private setting; No qualified personnel required; FDA approved DNA technology; 94% sensitivity reducing false negatives; Higher population coverage; and Cost-effectiveness. XytoTest™ is a self-sampling kit of cervical specimens for the analysis of DNA for the 14 high-risk strains of Human Papilloma Virus (HPV). Mel-Mont currently operates in the USA and emerging countries including in Latin and South America with a focus in Colombia, where the company has offices, and Mexico.

GVDI

Any post by budfoxhub is not a recommendation to buy, hold or sell a security.